Page header

Recommendation of the President – Zilbrysq (zilucoplan)

On 28 May 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 74/2026 on the inclusion of the medicinal product Zilbrysq (zilucoplan) in the reimbursement program B.157 “Treatment of patients with generalized myasthenia gravis (ICD-10: G70.0)”

Publication in Public Information Bulletin (BIP) >>